Spero Therapeutics, Inc. announced that it has entered into a securities purchase agreement with new investor Pfizer Inc. for private placement of 2,362,348 common shares $16.93 per share for gross proceeds of $39,994,551.64 on June 30, 2021. The company has raised funding as part of the Pfizer Breakthrough Growth Initiative. The company received funding from 1 investor pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.505 USD | -0.33% | -7.10% | +2.38% |
05-15 | Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q1 Revenue $9.3M | MT |
03-13 | Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.38% | 81.11M | |
+9.99% | 115B | |
+12.01% | 106B | |
-3.07% | 24.69B | |
-0.96% | 21.97B | |
-5.29% | 19.27B | |
-6.90% | 17.56B | |
-39.36% | 17.32B | |
+5.82% | 14.03B | |
+33.05% | 12.13B |
- Stock Market
- Equities
- SPRO Stock
- News Spero Therapeutics, Inc.
- Spero Therapeutics, Inc. announced that it has received $39.994552 million in funding from Pfizer Inc.